

---

**HEALTHCARE DRUGSTORES LIMITED**

---

**DIRECTORS' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2014**

FRIDAY



\*A3N3NU3T\*

A43

19/12/2014

#318

COMPANIES HOUSE

---

## HEALTHCARE DRUGSTORES LIMITED

---

### COMPANY INFORMATION

---

**DIRECTORS**

Mrs A J Cattee  
Mr P Cattee  
Mr K C Patel  
Mr J C Patel Jnr  
Mr K C Patel Jnr

**COMPANY SECRETARY**

Mr A R Patel

**REGISTERED NUMBER**

07264746

**REGISTERED OFFICE**

Lion House  
Red Lion Street  
London  
WC1R 4GB

**INDEPENDENT AUDITORS**

Saffery Champness  
Lion House  
Red Lion Street  
London  
WC1R 4GB

**BANKERS**

Barclays Bank Plc  
4th Floor, Bridgewater House  
Finzels Reach  
Counterslip  
Bristol  
BS1 6BX

**SOLICITORS**

Cripps LLP  
23 Kings Hill Avenue  
West Malling  
Kent  
ME19 4UA

---

## HEALTHCARE DRUGSTORES LIMITED

---

### CONTENTS

---

	Page
<b>Directors' report</b>	1 - 2
<b>Group strategic report</b>	3 - 4
<b>Independent auditors' report</b>	5 - 6
<b>Consolidated profit and loss account</b>	7
<b>Consolidated balance sheet</b>	8
<b>Company balance sheet</b>	9
<b>Consolidated cash flow statement</b>	10
<b>Notes to the financial statements</b>	11 - 28

---

## HEALTHCARE DRUGSTORES LIMITED

---

### DIRECTORS' REPORT FOR THE YEAR ENDED 31 MARCH 2014

---

The Directors present their report and the financial statements for the year ended 31 March 2014.

#### PRINCIPAL ACTIVITIES

The principal activity of the group continued to be that of retail pharmacy.

#### RESULTS

The loss for the year, after taxation, amounted to £698,785 (2013 - loss £530,827).

#### DIRECTORS

The Directors who served during the year were:

Mrs A J Cattee  
Mr P Cattee  
Mr K C Patel  
Mr J C Patel Jnr  
Mr K C Patel Jnr

#### POLITICAL AND CHARITABLE CONTRIBUTIONS

During the year the company made the following payments:

	2014	2013
	£	£
Charitable donations	5,331	3,643

#### EMPLOYEE INFORMATION

The group has undertaken several actions to keep its employees informed of matters affecting them as employees and the financial and economic factors affecting the performance of the group. This is achieved through consultations with the local branch managers and other employee representatives.

#### DISABLED EMPLOYEES

Applications for employment by disabled persons are given full and fair consideration for all vacancies in accordance with their particular aptitudes and abilities. In the event of employees becoming disabled, every effort is made to retrain them, in order that their employment with the group may continue. It is the policy of the group that training, career development and promotion opportunities should be available to all employees.

#### DIRECTORS' RESPONSIBILITIES STATEMENT

The Directors are responsible for preparing the Group strategic report, the Directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and the Group and of the profit or loss of the Group for that period. In preparing these financial statements, the Directors are required to:

---

## HEALTHCARE DRUGSTORES LIMITED

---

### DIRECTORS' REPORT FOR THE YEAR ENDED 31 MARCH 2014

---

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

#### DISCLOSURE OF INFORMATION TO AUDITORS


Each of the persons who are Directors at the time when this Directors' report is approved has confirmed that:

- so far as that Director is aware, there is no relevant audit information of which the Company and the Group's auditors are unaware, and
- that Director has taken all the steps that ought to have been taken as a Director in order to be aware of any relevant audit information and to establish that the Company and the Group's auditors are aware of that information.

#### AUDITORS

Under section 487(2) of the Companies Act 2006, Saffery Champness will be deemed to have been reappointed as auditors 28 days after these financial statements were sent to members or 28 days after the latest date prescribed for filing the accounts with the registrar, whichever is earlier.

This report was approved by the board and signed on its behalf.



**Mr J C Patel Jnr**  
Director

Date: 12.12.2014

---

## HEALTHCARE DRUGSTORES LIMITED

---

### GROUP STRATEGIC REPORT FOR THE YEAR ENDED 31 MARCH 2014

---

#### BUSINESS REVIEW

The group acquired two subsidiaries during the year which owned six pharmacies. The combined portfolio now comprises 33 retail pharmacies and all are performing to budget. The company's strategy is to continue driving growth through its existing portfolio.

##### Retail

The English pharmacy sector represents a secure, growing market, underpinned by an increasing need for dispensing of prescription drugs and a government that wants to see community pharmacies expand and improve the range of services they offer to relieve the burden on an overstretched NHS.

The group is a patient orientated service provider which dispenses pharmaceutical and other retail and over the counter products and provides a wide range of clinical services to its patients.

Its pharmacies are typically located in local communities, in or near health centres and GP surgeries, helping to deliver increased footfall amongst customers and develop strong relationships with the local healthcare community.

Prescription dispensing across the country has grown steadily at a rate of 5% over the last ten years. This growth is forecast to continue, driven by an aging population, an increased prevalence of long term conditions and advancements in drugs. The group business is well positioned to take advantage of this growth and continue driving its retail business going forward.

#### PRINCIPAL RISKS AND UNCERTAINTIES

Principal risks and uncertainties and risk management objectives and policies

##### Price risk

The group, through its investments, is exposed to the inherent risks of economic and financial market developments, including recession, inflation, availability of affordable credit and currency fluctuations that could lower revenues and reduce income. The current system of correcting generic reimbursement prices through the mechanism of "Category M" has continued through the current financial year. Category M was introduced with the new pharmacy contract in 2005 and allows the retail pharmacy industry to retain an amount of £540m of generic procurement profit annually. The system is therefore used retrospectively by the Department of Health to claw back surplus procurement profits from the Pharmacy. Through a continual business review process and monitoring of the business environment, the Directors of the company and the wider group seek to mitigate these potential risks.

##### Liquidity risk

The group is financed by way of bank loans, overdrafts and other loans of £27m as at 31 March 2014 (2013: £20.2m) at the year end. Banking facilities on competitive terms are secured until August 2017. The Directors believe the company has sufficient current and future cash reserves and facilities available for it to meet its liabilities including financing obligations for at least twelve months from the signing of the financial statements.

The Directors' assessment of the group's and the company's ability to adopt the going concern basis of accounting is set out in note 1 on page 11.

##### Interest rate risk

The group has various loan agreements in place, none of which have been hedged.

The Directors believe that this is appropriate given the nature of the group's business and long term financing

---

## HEALTHCARE DRUGSTORES LIMITED

---

### GROUP STRATEGIC REPORT (continued) FOR THE YEAR ENDED 31 MARCH 2014

---

agreement in place.

#### Credit risk

The group's principal financial assets are bank balances and cash, trade and other receivables. The credit risk on trade and other receivables is limited as the group's exposure is with Department of Health and customers. The amounts presented in the balance sheet are net of allowances for doubtful receivables. The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit ratings assigned by international credit rating agencies.

#### FINANCIAL KEY PERFORMANCE INDICATORS

Over the last few years, the directors have significantly improved profitability of the shops in the portfolio.

Group turnover in the year finished at £28.9m (2013: £23.2m).

The group's gross margins increased to 30.4% (2013: 29.9%) based on a gross profit of £8.8m for the year (2013: £6.9m)

Total administrative costs increased by £1.6m to £8.2m (2013: £6.6m). The business has enhanced its group infrastructure and support office function during the year to enable sustained future progress.

Overall these actions have enabled the Group with an operating profit of £694K (2013: £489K).

Interest costs have risen by £126K to £936K (2013: £810K).

Ongoing Government action continues to reduce reimbursement prices. The company has undertaken measures to mitigate the effect of this including enhanced purchasing and stock control processes and thorough appraisals of individual branch profitability.

This report was approved by the board and signed on its behalf.



**Mr J C Patel Jnr**  
Director

Date: 12.12.2014

---

## HEALTHCARE DRUGSTORES LIMITED

---

### INDEPENDENT AUDITORS' REPORT TO THE SHAREHOLDERS OF HEALTHCARE DRUGSTORES LIMITED

---

We have audited the financial statements of Healthcare Drugstores Limited for the year ended 31 March 2014, set out on pages 7 to 28. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body, for our audit work, for this report, or for the opinions we have formed.

#### RESPECTIVE RESPONSIBILITIES OF DIRECTORS AND AUDITORS

As explained more fully in the Directors' responsibilities statement set out on pages 1 - 3, the Directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

#### SCOPE OF THE AUDIT OF THE FINANCIAL STATEMENTS

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the Group's and the parent Company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the Directors; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Group strategic report and the Directors' report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

#### OPINION ON FINANCIAL STATEMENTS

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and the parent Company's affairs as at 31 March 2014 and of the Group's loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

#### OPINION ON OTHER MATTER PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion the information given in the Group strategic report and the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements.



---

HEALTHCARE DRUGSTORES LIMITED

---


INDEPENDENT AUDITORS' REPORT TO THE SHAREHOLDERS OF HEALTHCARE DRUGSTORES  
LIMITED

---

**MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION**

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent Company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent Company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.



Roger Wareham (Senior statutory auditor)

for and on behalf of  
**Saffery Champness**

Lion House  
Red Lion Street  
London  
WC1R 4GB

Date: 18.12.2014

**HEALTHCARE DRUGSTORES LIMITED**

**CONSOLIDATED PROFIT AND LOSS ACCOUNT  
FOR THE YEAR ENDED 31 MARCH 2014**

	Note	2014 £	2013 £
<b>TURNOVER</b>	1,2	<b>28,871,407</b>	<b>23,233,495</b>
Cost of sales		<u>(20,108,414)</u>	<u>(16,293,108)</u>
<b>GROSS PROFIT</b>		<b>8,762,993</b>	<b>6,940,387</b>
Administrative expenses		<b>(8,157,404)</b>	<b>(6,553,953)</b>
Other operating income	3	<u>88,873</u>	<u>102,929</u>
<b>OPERATING PROFIT</b>	4	<b>694,462</b>	<b>489,363</b>
<b>EXCEPTIONAL ITEMS</b>			
Net (loss)/profit on disposal of pharmacy branches	8	<u>-</u>	<u>(289,792)</u>
<b>PROFIT ON ORDINARY ACTIVITIES BEFORE INTEREST</b>		<b>694,462</b>	<b>199,571</b>
Interest receivable and similar income		<b>6,129</b>	<b>4,953</b>
Interest payable and similar charges	7	<u>(935,767)</u>	<u>(809,827)</u>
<b>LOSS ON ORDINARY ACTIVITIES BEFORE TAXATION</b>		<b>(235,176)</b>	<b>(605,303)</b>
Tax on loss on ordinary activities	9	<u>(463,609)</u>	<u>74,476</u>
<b>LOSS FOR THE FINANCIAL YEAR</b>	19	<u><b>(698,785)</b></u>	<u><b>(530,827)</b></u>

All amounts relate to continuing operations.

There were no recognised gains and losses for 2014 or 2013 other than those included in the Profit and loss account.


The notes on pages 11 to 28 form part of these financial statements.

**HEALTHCARE DRUGSTORES LIMITED**  
**REGISTERED NUMBER: 07264746**

**CONSOLIDATED BALANCE SHEET**  
**AS AT 31 MARCH 2014**

	Note	£	2014 £	£	2013 £
<b>FIXED ASSETS</b>					
Intangible assets	10		19,100,432		14,348,508
Tangible assets	11		1,443,812		907,419
Investments	12		-		-
			<u>20,544,244</u>		<u>15,255,927</u>
<b>CURRENT ASSETS</b>					
Stocks	13	1,807,212		1,427,596	
Debtors	14	5,986,461		5,561,193	
Cash at bank and in hand		520,894		274,069	
		<u>8,314,567</u>		<u>7,262,858</u>	
<b>CREDITORS: amounts falling due within one year</b>	15	<u>(5,902,193)</u>		<u>(4,238,187)</u>	
<b>NET CURRENT ASSETS</b>			<u>2,412,374</u>		<u>3,024,671</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			<u>22,956,618</u>		<u>18,280,598</u>
<b>CREDITORS: amounts falling due after more than one year</b>	16		<u>(25,232,256)</u>		<u>(19,857,451)</u>
<b>NET LIABILITIES</b>			<u>(2,275,638)</u>		<u>(1,576,853)</u>
<b>CAPITAL AND RESERVES</b>					
Called up share capital	18		100		100
Profit and loss account	19		<u>(2,275,738)</u>		<u>(1,576,953)</u>
<b>SHAREHOLDERS' DEFICIT</b>	20		<u>(2,275,638)</u>		<u>(1,576,853)</u>

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:



**Mr J C Patel Jnr**  
Director

Date: 12.12.2014

The notes on pages 11 to 28 form part of these financial statements.

**HEALTHCARE DRUGSTORES LIMITED**  
**REGISTERED NUMBER: 07264746**

**COMPANY BALANCE SHEET**  
**AS AT 31 MARCH 2014**

	Note	£	2014 £	£	2013 £
<b>FIXED ASSETS</b>					
Investments	12		20,210,445		19,620,577
<b>CURRENT ASSETS</b>					
Debtors	14	12,132		37,693	
Cash at bank		564		215,933	
		<u>12,696</u>		<u>253,626</u>	
<b>CREDITORS: amounts falling due within one year</b>	15	<u>(702,615)</u>		<u>(254,315)</u>	
<b>NET CURRENT LIABILITIES</b>			<u>(689,919)</u>		<u>(689)</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			<u>19,520,526</u>		<u>19,619,888</u>
<b>CREDITORS: amounts falling due after more than one year</b>	16		<u>(20,132,256)</u>		<u>(19,857,451)</u>
<b>NET LIABILITIES</b>			<u>(611,730)</u>		<u>(237,563)</u>
<b>CAPITAL AND RESERVES</b>					
Called up share capital	18		100		100
Profit and loss account	19		<u>(611,830)</u>		<u>(237,663)</u>
<b>SHAREHOLDERS' DEFICIT</b>	20		<u>(611,730)</u>		<u>(237,563)</u>

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:



**Mr J C Patel Jnr**  
Director

Date: 12.12.2014

The notes on pages 11 to 28 form part of these financial statements.

**HEALTHCARE DRUGSTORES LIMITED**

**CONSOLIDATED CASH FLOW STATEMENT  
FOR THE YEAR ENDED 31 MARCH 2014**

	Note	2014 £	2013 £
Net cash flow from operating activities	22	821,170	1,045,087
Returns on investments and servicing of finance	23	(123,538)	(1,495)
Taxation	23	(402,448)	461,251
Capital expenditure and financial investment	23	(520,401)	(156,789)
Acquisitions and disposals	23	(5,219,702)	100,000
<b>CASH (OUTFLOW)/INFLOW BEFORE FINANCING</b>		<b>(5,444,919)</b>	<b>1,448,054</b>
Financing	23	5,309,328	(872,248)
<b>(DECREASE)/INCREASE IN CASH IN THE YEAR</b>		<b>(135,591)</b>	<b>575,806</b>

**RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET FUNDS/DEBT  
FOR THE YEAR ENDED 31 MARCH 2014**

	2014 £	2013 £
(Decrease)/Increase in cash in the year	(135,591)	575,806
Cash (inflow)/outflow from (increase)/decrease in debt and lease financing	(5,309,328)	872,248
<b>CHANGE IN NET DEBT RESULTING FROM CASH FLOWS</b>	<b>(5,444,919)</b>	<b>1,448,054</b>
Other non-cash changes	(665,477)	(803,378)
<b>MOVEMENT IN NET DEBT IN THE YEAR</b>	<b>(6,110,396)</b>	<b>644,676</b>
Net debt at 1 April 2013	(19,922,199)	(20,566,875)
<b>NET DEBT AT 31 MARCH 2014</b>	<b>(26,032,595)</b>	<b>(19,922,199)</b>

The notes on pages 11 to 28 form part of these financial statements.

---

## HEALTHCARE DRUGSTORES LIMITED

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2014

---

#### 1. ACCOUNTING POLICIES

##### 1.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention and in accordance with applicable accounting standards.

The group had a deficit on its balance sheet reserves as at 31 March 2014. The key creditor and shareholder as detailed in note 28 has confirmed its continued financial support for the foreseeable future.

The directors are of the opinion that, on review of the financial position of the group and the continued financial support detailed above, they have a reasonable expectation that the group has adequate resources to continue in operation for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements.

##### 1.2 Compliance with accounting standards

The financial statements are prepared in accordance with applicable United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), which have been applied consistently (except as otherwise stated).

##### 1.3 Basis of consolidation

The financial statements consolidate the accounts of Healthcare Drugstores Limited and all of its subsidiary undertakings ('subsidiaries').

The results of subsidiaries acquired during the year are included from the effective date of acquisition.

Profits or losses on intra-group transactions are eliminated in full on consolidation. On acquisition of a subsidiary, all of the subsidiary's assets and liabilities which exist at the date of acquisition are recorded at their fair values reflecting their condition at that date.

##### 1.4 Turnover

Turnover comprises revenue recognised by the Company in respect of goods and services supplied during the year, exclusive of Value Added Tax and trade discounts.

A revenue recognition adjustment is made in respect of the estimated recovery of excess profit from NHS income paid through the Category M Pricing Policy in the following year.

---

## HEALTHCARE DRUGSTORES LIMITED

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2014

---

#### 1. ACCOUNTING POLICIES (continued)

##### 1.5 Goodwill and retail pharmacy licences

Goodwill arising on consolidation, representing the excess of fair value of the consideration given over the fair values of the identifiable net assets acquired, is capitalised and is amortised on a straight line basis over its estimated useful life of 20 years.

The cost of acquiring retail pharmacy licences is subject to an annual impairment review by the directors in accordance with FRS 10. The directors consider that these have an indefinite life and are therefore not amortised.

The directors believe that the right for dispensing UK NHS prescriptions, being the pharmacy licence which is attached to a particular pharmacy, has a continuing value. Such rights, conferred by the Department of Health as contracts to dispense prescriptions, are not generally granted to new pharmacies in the same locality. Any deficiency arising from the impairment review is written off to the profit and loss account in the year in which it arises. Any increases in value are not recognised in the financial statements.

This departure from the requirements of the Companies Act 2006 is, in the opinion of the directors, necessary for the financial statements to give a true and fair view.

##### 1.6 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is not charged on freehold land. Depreciation on other tangible fixed assets is provided at rates calculated to write off the cost of those assets, less their estimated residual value, over their expected useful lives on the following bases:

Freehold property	-	1% per annum straight line
Leasehold land and buildings	-	Over the life of the lease
Plant and machinery	-	25% per annum straight line
Motor vehicles	-	25% per annum straight line
Fixtures, fittings and equipment	-	15% per annum reducing balance

##### 1.7 Investments

Subsidiary undertakings

Investments in subsidiaries are valued at cost less provision for impairment.

##### 1.8 Operating leases

Rentals under operating leases are charged to the Profit and loss account on a straight line basis over the lease term.

##### 1.9 Stocks

Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.

---

## HEALTHCARE DRUGSTORES LIMITED

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2014

---

#### 1. ACCOUNTING POLICIES (continued)

##### 1.10 Deferred taxation

Full provision is made for deferred tax assets and liabilities arising from all timing differences between the recognition of gains and losses in the financial statements and recognition in the tax computation.

A net deferred tax asset is recognised only if it can be regarded as more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

Deferred tax assets and liabilities are calculated at the tax rates expected to be effective at the time the timing differences are expected to reverse.

Deferred tax assets and liabilities are not discounted.

##### 1.11 Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the balance sheet date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Profit and loss account.

##### 1.12 Pensions

The Company operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Company to the fund in respect of the year.

#### 2. TURNOVER

All turnover arose within the United Kingdom.

#### 3. OTHER OPERATING INCOME

	2014 £	2013 £
Rent receivable	<u>88,873</u>	<u>102,929</u>



# HEALTHCARE DRUGSTORES LIMITED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2014

### 4. OPERATING PROFIT

The operating profit is stated after charging:

	2014 £	2013 £
Amortisation - intangible fixed assets	717,640	402,381
Depreciation of tangible fixed assets:		
- owned by the group	216,158	192,297
Operating lease rentals:		
- plant and machinery	256	-
- other operating leases	828,679	862,327
Profit/loss on sale of tangible assets	141	-
	<u>717,640</u>	<u>402,381</u>

During the year, no Director received any emoluments (2013 - £NIL).

### 5. AUDITORS' REMUNERATION

	2014 £	2013 £
Fees payable to the Company's auditor and its associates for the audit of the Company's annual accounts	16,750	16,750
Fees payable to the Company's auditor and its associates in respect of:		
All other non-audit services not included above	19,325	8,750
	<u>16,750</u>	<u>16,750</u>

### 6. STAFF COSTS

Staff costs were as follows:

	2014 £	2013 £
Wages and salaries	3,771,071	3,072,013
Social security costs	269,804	262,765
Other pension costs	11,057	-
	<u>3,771,071</u>	<u>3,072,013</u>
	<u>4,051,932</u>	<u>3,334,778</u>

The average monthly number of employees, including the Directors, during the year was as follows:

	2014 No.	2013 No.
Distribution staff	163	152
	<u>163</u>	<u>152</u>

---

**HEALTHCARE DRUGSTORES LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2014**

---

**7. INTEREST PAYABLE**

	2014 £	2013 £
On bank loans and overdrafts	128,211	5,273
On other loans	807,556	803,379
On finance leases and hire purchase contracts	-	1,175
	<u>935,767</u>	<u>809,827</u>

**8. EXCEPTIONAL ITEMS**

	2014 £	2013 £
Disposal of pharmacy branches	-	289,792
	<u>-</u>	<u>289,792</u>

**9. TAXATION**

	2014 £	2013 £
<b>Analysis of tax charge/(credit) in the year</b>		
<b>Current tax (see note below)</b>		
UK corporation tax charge on loss for the year	241,270	50,132
Adjustments in respect of prior periods	126,444	(54,377)
<b>Total current tax</b>	<u>367,714</u>	<u>(4,245)</u>
<b>Deferred tax (see note 17)</b>		
Origination and reversal of timing differences	95,895	(70,231)
<b>Tax on loss on ordinary activities</b>	<u>463,609</u>	<u>(74,476)</u>

---

**HEALTHCARE DRUGSTORES LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2014**

---

**9. TAXATION (continued)**

**Factors affecting tax charge for the year**

The tax assessed for the year is higher than (2013 - *lower than*) the standard rate of corporation tax in the UK of 23% (2013 - 20%). The differences are explained below:

	2014 £	2013 £
Loss on ordinary activities before tax	<u>(235,176)</u>	<u>(605,303)</u>
Loss on ordinary activities multiplied by standard rate of corporation tax in the UK of 23% (2013 - 20%)	(54,090)	(121,061)
<b>Effects of:</b>		
Non-tax deductible amortisation of goodwill and impairment	165,057	80,476
Expenses not deductible for tax purposes, other than goodwill amortisation and impairment	189,007	45,211
Capital allowances for year in excess of depreciation	(25,207)	(10,810)
Utilisation of tax losses	(35,390)	-
Adjustments to tax charge in respect of prior periods	126,444	(54,377)
Short term timing difference leading to an increase (decrease) in taxation	4,071	-
Chargeable disposals	-	53,930
Other tax adjustments	(2,178)	2,386
<b>Current tax charge/(credit) for the year (see note above)</b>	<u><b>367,714</b></u>	<u><b>(4,245)</b></u>

Other tax adjustments reflect marginal rate relief.

The group has estimated losses of £4,628,102 (2013: £4,781,971) available for carry forward against future trading profits.

As at 31 March 2014 a deferred tax asset existed in respect of losses carried forward of £1,452,000 (2013: £1,099,853), based on an expected future tax rate of 20% (2013: 23%). The full deferred tax has not been recognised as the necessary conditions have not been met.

---

**HEALTHCARE DRUGSTORES LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2014**

---

**10. INTANGIBLE FIXED ASSETS**

<b>Group</b>	<b>Goodwill £</b>	<b>Retail pharmacy licences £</b>	<b>Total £</b>
<b>Cost</b>			
At 1 April 2013	8,047,621	7,508,030	15,555,651
Additions	-	377,299	377,299
On acquisition of subsidiaries	3,411,639	2,642,000	6,053,639
	<u>11,459,260</u>	<u>10,527,329</u>	<u>21,986,589</u>
<b>Amortisation</b>			
At 1 April 2013	1,207,143	-	1,207,143
Charge for the year	572,963	144,677	717,640
On acquisition of subsidiaries	-	961,374	961,374
	<u>1,780,106</u>	<u>1,106,051</u>	<u>2,886,157</u>
<b>Net book value</b>			
At 31 March 2014	<u>9,679,154</u>	<u>9,421,278</u>	<u>19,100,432</u>
<i>At 31 March 2013</i>	<u>6,840,478</u>	<u>7,508,030</u>	<u>14,348,508</u>

**HEALTHCARE DRUGSTORES LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2014**

**11. TANGIBLE FIXED ASSETS**

<b>Group</b>	<b>Freehold property £</b>	<b>Leasehold Land and building £</b>	<b>Plant and machinery £</b>	<b>Motor vehicles £</b>	<b>Fixtures, fittings and equipment £</b>	<b>Total £</b>
<b>Cost</b>						
At 1 April 2013	-	374,360	181,264	-	1,671,863	2,227,487
Additions	-	-	-	33,079	110,323	143,402
Disposals	-	-	-	(3,500)	-	(3,500)
On acquisition of subsidiaries	477,387	4	-	25,012	107,187	609,590
At 31 March 2014	477,387	374,364	181,264	54,591	1,889,373	2,976,979
<b>Depreciation</b>						
At 1 April 2013	-	257,111	170,562	-	892,395	1,320,068
Charge for the year	3,770	41,018	7,410	14,413	149,547	216,158
On disposals	-	-	-	(3,059)	-	(3,059)
At 31 March 2014	3,770	298,129	177,972	11,354	1,041,942	1,533,167
<b>Net book value</b>						
At 31 March 2014	473,617	76,235	3,292	43,237	847,431	1,443,812
At 31 March 2013	-	117,249	10,702	-	779,468	907,419

freehold land and buildings includes land with a value of £116,796 on which no depreciation charge is made.

**12. FIXED ASSET INVESTMENTS**

<b>Company</b>	<b>Investments in subsidiary companies £</b>	<b>Loans to subsidiaries £</b>	<b>Total £</b>
<b>Cost or valuation</b>			
At 1 April 2013	2,207,272	17,413,305	19,620,577
Additions	-	730,490	730,490
Disposals	-	(140,622)	(140,622)
At 31 March 2014	2,207,272	18,003,173	20,210,445
<b>Net book value</b>			
At 31 March 2014	2,207,272	18,003,173	20,210,445
At 31 March 2013	2,207,272	17,413,305	19,620,577

**HEALTHCARE DRUGSTORES LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2014**

**12. FIXED ASSET INVESTMENTS (continued)**

Details of the principal subsidiaries can be found under note number 29.

In the opinion of the directors, the aggregate value of the company's investment in subsidiary undertakings is not less than the amount included in the balance sheet.

The loans to group undertakings represent amounts due from ABC Drug Stores Limited. The loan is unsecured with no fixed repayment terms. Interest is charged at a rate of 3.5% per annum above the Bank of England base rate.

**13. STOCKS**

	<b>Group</b>		<b>Company</b>	
	<b>2014</b>	<b>2013</b>	<b>2014</b>	<b>2013</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Finished goods and goods for resale	<b>1,807,212</b>	<b>1,427,596</b>	-	-

**14. DEBTORS**

	<b>Group</b>		<b>Company</b>	
	<b>2014</b>	<b>2013</b>	<b>2014</b>	<b>2013</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Trade debtors	<b>3,936,582</b>	<b>3,375,950</b>	-	-
Other debtors	<b>1,448,768</b>	<b>1,612,970</b>	<b>12,132</b>	<b>37,693</b>
Prepayments and accrued income	<b>324,333</b>	<b>184,817</b>	-	-
Deferred tax asset (see note 17)	<b>276,778</b>	<b>387,456</b>	-	-
	<b>5,986,461</b>	<b>5,561,193</b>	<b>12,132</b>	<b>37,693</b>

**15. CREDITORS:  
Amounts falling due within one year**

	<b>Group</b>		<b>Company</b>	
	<b>2014</b>	<b>2013</b>	<b>2014</b>	<b>2013</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Bank loans and overdrafts	<b>1,321,233</b>	<b>338,817</b>	-	-
Trade creditors	<b>3,416,758</b>	<b>2,611,863</b>	-	-
Amounts owed to group undertakings	-	-	<b>534,754</b>	<b>16,796</b>
Corporation tax	<b>207,273</b>	<b>242,006</b>	<b>163,860</b>	<b>217,791</b>
Other taxation and social security	<b>88,386</b>	<b>69,679</b>	-	-
Other creditors	<b>542,852</b>	<b>411,247</b>	-	-
Accruals and deferred income	<b>325,691</b>	<b>564,575</b>	<b>4,001</b>	<b>19,728</b>
	<b>5,902,193</b>	<b>4,238,187</b>	<b>702,615</b>	<b>254,315</b>

# HEALTHCARE DRUGSTORES LIMITED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2014

### 15. CREDITORS:

#### Amounts falling due within one year (continued)

The bank loan and overdraft is secured by way of a fixed and floating charge over the company's assets and a specific charge over the leasehold property and other assets of various pharmacy branches operated.

A legal charge over all shares held by Healthcare Drugstores Limited in ABC Drug Stores Limited

### 16. CREDITORS:

#### Amounts falling due after more than one year

	<b>Group</b>		<b>Company</b>	
	<b>2014</b>	<b>2013</b>	<b>2014</b>	<b>2013</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Bank loans	5,100,000	-	-	-
Other loans	20,132,256	19,857,451	20,132,256	19,857,451
	<b>25,232,256</b>	<b>19,857,451</b>	<b>20,132,256</b>	<b>19,857,451</b>

Included within the above are amounts falling due as follows:

	<b>Group</b>		<b>Company</b>	
	<b>2014</b>	<b>2013</b>	<b>2014</b>	<b>2013</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
<b>Between one and two years</b>				
Bank loans	600,000	-	-	-
<b>Between two and five years</b>				
Bank loans	4,500,000	-	-	-
<b>Over five years</b>				
Other loans	20,132,256	19,857,451	20,132,256	19,857,451

Creditors include amounts not wholly repayable within 5 years as follows:

	<b>Group</b>		<b>Company</b>	
	<b>2014</b>	<b>2013</b>	<b>2014</b>	<b>2013</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Repayable other than by instalments	20,132,256	19,857,451	20,132,256	19,857,451

---

## HEALTHCARE DRUGSTORES LIMITED

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2014

---

#### 16. CREDITORS:

##### Amounts falling due after more than one year (continued)

Bank loans and overdrafts due within one year and after more than one year amounting to £6,421,233 (2013: £338,817) as at the year end were secured as follows:

- Unlimited inter-company guarantees
- Cross guarantee and debentures, incorporating all freehold and leasehold properties owned by the company and subsidiaries.
- A legal charge over all shares held by Healthcare Drugstores Limited in ABC Drug Stores Limited
- A legal charge over all shares held by ABC Drug Stores Limited in Medex Health Limited

The bank loan facilities now in place have a maturity date of 4 years ending August 2017. The loans bear interest rate 2.65% per annum above LIBOR.

#### 17. DEFERRED TAXATION

	<u>Group</u>		<u>Company</u>	
	<u>2014</u>	<u>2013</u>	<u>2014</u>	<u>2013</u>
	£	£	£	£
At beginning of year	387,456	317,225	-	-
Movement during the year (P&L)	(95,895)	70,231	-	-
On acquisition of subsidiary	(14,783)	-	-	-
At end of year	<u>276,778</u>	<u>387,456</u>	<u>-</u>	<u>-</u>

The deferred taxation balance is made up as follows:

	<u>Group</u>		<u>Company</u>	
	<u>2014</u>	<u>2013</u>	<u>2014</u>	<u>2013</u>
	£	£	£	£
Accelerated capital allowances	17,170	23,356	-	-
Tax losses brought forward	(290,400)	(410,812)	-	-
Other timing differences	(3,548)	-	-	-
	<u>(276,778)</u>	<u>(387,456)</u>	<u>-</u>	<u>-</u>

The deferred tax provision has been calculated using the company's expected rate of UK corporation tax of 20% (2013: 23%)



---

HEALTHCARE DRUGSTORES LIMITED

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2014

---

18. SHARE CAPITAL

	2014 £	2013 £
<b>Allotted, called up and fully paid</b>		
50 Ordinary 'A' shares of £1 each	50	50
50 Ordinary 'B' shares of £1 each	50	50
	<hr/>	<hr/>
	100	100
	<hr/>	<hr/>

All shares rank pari passu.

19. RESERVES

	<b>Profit and loss account £</b>
<b>Group</b>	
At 1 April 2013	(1,576,953)
Loss for the financial year	(698,785)
	<hr/>
At 31 March 2014	(2,275,738)
	<hr/>
<b>Company</b>	<b>Profit and loss account £</b>
At 1 April 2013	(237,663)
Loss for the financial year	(374,167)
	<hr/>
At 31 March 2014	(611,830)
	<hr/>

---

HEALTHCARE DRUGSTORES LIMITED

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2014

---

20. RECONCILIATION OF MOVEMENT IN SHAREHOLDERS' DEFICIT

	2014	2013
Group	£	£
Opening shareholders' deficit	(1,576,853)	(1,046,026)
Loss for the financial year	(698,785)	(530,827)
Closing shareholders' deficit	<u>(2,275,638)</u>	<u>(1,576,853)</u>
Company	2014	2013
	£	£
Opening shareholders' deficit	(237,563)	(188,158)
Loss for the financial year	(374,167)	(49,405)
Closing shareholders' deficit	<u>(611,730)</u>	<u>(237,563)</u>

The Company has taken advantage of the exemption contained within section 408 of the Companies Act 2006 not to present its own Profit and loss account.

The loss for the year dealt with in the accounts of the Company was £374,167 (2013 - £-49,405).

# HEALTHCARE DRUGSTORES LIMITED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2014

### 21. ACQUISITIONS AND DISPOSALS

During the year the group acquired incorporated business Medex Health Limited on 2 April 2013, using acquisition accounting. The fair values of the identifiable assets and liabilities at the date of disposal (including goodwill) were as follows:

#### Acquisitions

	Vendors' book value £	Fair value to the group £
<b>Assets and liabilities acquired</b>		
Tangible fixed assets	598,929	598,929
Intangible fixed assets	1,680,626	1,680,626
Stocks	277,333	277,333
Debtors	671,401	671,401
Cash at bank	679,512	679,512
Loans and finance leases	(1,049,389)	(1,049,389)
Other creditors and provisions	(1,050,349)	(1,050,349)
Net assets acquired	<u>1,808,063</u>	<u>1,808,063</u>
<b>Satisfied by</b>		
Consideration:		
Cash		5,156,008
Acquisition costs		63,694
		<u>5,219,702</u>
Goodwill arising on consolidation (see note 10)		<u>3,411,639</u>

### 22. NET CASH FLOW FROM OPERATING ACTIVITIES

	2014 £	2013 £
Operating profit	694,462	489,363
Amortisation of intangible fixed assets	717,640	402,381
Depreciation of tangible fixed assets	216,158	192,297
Loss on disposal of tangible fixed assets	141	-
(Increase)/decrease in stocks	(102,283)	96,687
Decrease in debtors	135,453	75,979
Decrease in creditors	(840,401)	(211,620)
Net cash inflow from operating activities	<u>821,170</u>	<u>1,045,087</u>

**HEALTHCARE DRUGSTORES LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2014**

**23. ANALYSIS OF CASH FLOWS FOR HEADINGS NETTED IN CASH FLOW STATEMENT**

	2014 £	2013 £
<b>Returns on investments and servicing of finance</b>		
Interest received	6,129	4,953
Interest paid	(129,667)	(5,273)
Hire purchase interest	-	(1,175)
<b>Net cash outflow from returns on investments and servicing of finance</b>	<u>(123,538)</u>	<u>(1,495)</u>
	2014 £	2013 £
<b>Taxation</b>		
Corporation tax	<u>(402,448)</u>	<u>461,251</u>
	2014 £	2013 £
<b>Capital expenditure and financial investment</b>		
Purchase of intangible fixed assets	(377,299)	(7,805)
Purchase of tangible fixed assets	(143,402)	(148,984)
Sale of tangible fixed assets	300	-
<b>Net cash outflow from capital expenditure</b>	<u>(520,401)</u>	<u>(156,789)</u>
	2014 £	2013 £
<b>Acquisitions and disposals</b>		
Purchase of incorporated business	(5,899,214)	-
Cash at bank acquired with subsidiary undertakings	679,512	-
Disposal of unincorporated business	-	100,000
<b>Net cash (outflow)/inflow from acquisitions and disposals</b>	<u>(5,219,702)</u>	<u>100,000</u>
	2014 £	2013 £
<b>Financing</b>		
New secured loans	6,000,000	-
Repayment of loans	(300,000)	-
Other new loans	-	1,850,000
Repayment of other loans	(390,672)	(2,722,248)
<b>Net cash inflow/(outflow) from financing</b>	<u>5,309,328</u>	<u>(872,248)</u>

---

**HEALTHCARE DRUGSTORES LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2014**

---

**24. ANALYSIS OF CHANGES IN NET DEBT**

	1 April 2013 £	Cash flow £	Other non-cash changes £	31 March 2014 £
Cash at bank and in hand	274,069	246,825	-	520,894
Bank overdraft	(338,817)	(382,416)	-	(721,233)
	<u>(64,748)</u>	<u>(135,591)</u>	<u>-</u>	<u>(200,339)</u>
<b>Debt:</b>				
Debts due within one year	-	(5,309,328)	4,709,328	(600,000)
Debts falling due after more than one year	(19,857,451)	-	(5,374,805)	(25,232,256)
	<u>(19,922,199)</u>	<u>(5,444,919)</u>	<u>(665,477)</u>	<u>(26,032,595)</u>
<b>Net debt</b>	<u>(19,922,199)</u>	<u>(5,444,919)</u>	<u>(665,477)</u>	<u>(26,032,595)</u>

**25. MAJOR NON-CASH TRANSACTIONS**

Other non-cash changes represent interest accrual on loans during the year.

**26. PENSION COMMITMENTS**

The Group operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Group in an independently administered fund. The pension cost charge represents contributions payable by the Group to the fund and amounted to £11,057 (2013 - £nil). Contributions totalling £17,700 (2013 - £nil) were payable to the fund at the balance sheet date and are included in creditors

**27. OPERATING LEASE COMMITMENTS**

At 31 March 2014 the Group had annual commitments under non-cancellable operating leases as follows:

	Land and buildings 2014 £	2013 £
<b>Group</b>		
<b>Expiry date:</b>		
Within 1 year	167,000	40,500
Between 2 and 5 years	434,700	313,487
After more than 5 years	<u>449,305</u>	<u>431,052</u>

---

## HEALTHCARE DRUGSTORES LIMITED

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2014

---

#### 28. RELATED PARTY TRANSACTIONS

The company has taken advantage of the exemption available in FRS 8 "Related party disclosures" whereby it has not disclosed transactions with the ultimate parent company or any wholly owned subsidiary undertaking of the group.

During the year the following transactions occurred with Day Lewis Plc and its subsidiaries of which K C Patel, a director, has a controlling interest.

The company made sales to and received other income of £116,385 (2013: £121,616) from Day Lewis Plc and paid £250,000 (2013: £250,000) in respect of management charges for accountancy, book keeping and general administration work carried out at their offices on behalf of the company. The company was also recharged £615,119 (2013: £629,346) in respect of expenses paid by Day Lewis Plc on behalf of the company. At the balance sheet date £34,021 (2013: £59,993) was receivable from Day Lewis Plc for other expenses paid on behalf of the company.

The company sold goods of £1,283,485 (2013: £1,144,796) to Day Lewis Medical Limited and purchased goods from Day Lewis Medical Limited of £2,787,754 (2013: £5,980,711). The company was also recharged £78,824 (2013: £72,344) in respect of expenses paid by Day Lewis Medical Limited on behalf of the company. The company charged £197,848 (2013: £nil) in respect of expenses paid for Day Lewis Medical Limited. At the balance sheet date £20,666 (2013: -£65,294) was receivable from Day Lewis Medical Limited.

The company was recharged £57,975 (2013: £58,942) in respect of expenses paid by Day Lewis Chemists Limited on behalf of the company. At the balance sheet date £4,550 (2013: £37,794) was payable to Day Lewis Chemists Limited.

The company paid expenses on behalf of Tayzana Limited of £9,459 (2013: £4,378). At the balance sheet date £nil (2013: £2,076) was due to the company.

The company paid rent to the following:

Rupa Patel, K C Patel's daughter, £25,000 (2013: £25,102)  
Joseph Cattee, P Cattee's son, £25,000 (2013: £25,102)

The company charged interest of £2,320 (2013: £1,254) during the year on loan of £67,992 made to Rupa Patel, K C Patel's daughter. At the balance sheet date £nil (2013: £67,992) was due to the company.

The company charged interest of £2,320 (2013: £1,254) during the year on loan of £67,992 made to Joseph Cattee, P Cattee's son. At the balance sheet date £nil (2013: £67,992) was due to the company.

The company purchased goods of £136,107 (2013: £128,346) from Swingward Limited, a company in which K C Patel has a controlling interest. At the balance sheet date £13,354 (2013: £30,995) was payable to Swingward Limited.

During the period P Cattee, a director and shareholder, charged interest of £717,035 (2013: £704,194) on the loan at 3.5% above the Bank of England base rate. The loan is unsecured and due for repayment in full by 19 November 2020, together with any unpaid interest. At the period end a balance of £18,125,337 (2013: £17,673,949) was outstanding.

Horizon Drugstores Limited, a company registered in Jersey is a shareholder. K C Patel, a director of Healthcare Drugstores Limited, is also a director of Horizon Drugstores Limited. During the period interest of £13,455 (2013: £96,377) was charged on the loan at 3.5% above the Bank of England base rate. The loan is unsecured and due for repayment in full by 19 November 2020, together with any unpaid interest. At the period end a balance of £344,148 (2013: £330,694) was outstanding.

---

## HEALTHCARE DRUGSTORES LIMITED

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2014

---

#### 28. RELATED PARTY TRANSACTIONS (continued)

During the year K C Patel, a director charged interest of £75,610 (2013: £2,808) on the loan at 3.5% above the Bank of England base rate. At the period end a balance of £1,662,771 (2013: £1,852,808) was outstanding.

The group had the following transactions and balances with PCT Healthcare Limited and P & A J Cattee (Wholesale) Limited, companies in which P Cattee is materially interested as a director and shareholder:

	2014 £
Sales	209,943
Purchases	1,395,626
Management charges payable	68,000
Other expense recharges	61,043
Debtors	53,224
Creditors	142,797

#### 29. PRINCIPAL SUBSIDIARIES

Company name	Country	Percentage Shareholding	Description
ABC Drug Stores Ltd	England & Wales	100%	Retail pharmacy
Medex Health Ltd	England & Wales	100%	Retail pharmacy
Winshill Pharmacy Ltd	England & Wales	100%	Dormant